A groundbreaking machine designed to keep donated lungs viable outside the body could significantly enhance lung transplantation rates in England and Wales. Current statistics reveal that a staggering four in every five donated lungs go unused, highlighting an urgent need for innovation in the field of organ transplantation.
A Critical Situation
With the UK boasting one of the lowest lung transplantation rates globally, the need for effective solutions has never been more pressing. According to NHS Blood and Transplant, 170 individuals, including six children, are currently on the waiting list for lung transplants. Many of these patients face long waits, often exceeding a year, with some tragically passing away before a suitable organ becomes available. Alarmingly, about 20% of adults on the transplant list die within a year, a statistic that underscores the desperate need for action.
One significant factor contributing to this issue is the poor utilisation of donated organs. Currently, only 23% of all donated lungs are successfully transplanted, with many being rejected due to concerns over organ quality and logistical challenges within healthcare facilities.
The XVIVO Perfusion System
The National Institute for Health and Care Excellence (NICE) has recently issued draft guidance advocating for the wider adoption of the XVIVO perfusion system within the NHS. This innovative technology could potentially salvage up to 80% of the lungs that currently go to waste. By maintaining the organs at body temperature and circulating a blood-like fluid while ventilating them, the machine allows medical teams to assess lung function, treat infections, and manage any complications before transplantation.
Although the XVIVO system has undergone trials at three adult transplant centres, NICE’s endorsement aims to ensure that all transplant facilities, regardless of size, can benefit from this promising technology. The draft guidance sets the stage for a four-year evaluation period to assess the system’s effectiveness and cost-efficiency.
Dr. Anastasia Chalkidou, Director of the Healthtech Programme at NICE, emphasised the importance of this technology: “Every donated lung is a precious gift, and right now too many of them never reach a patient who needs them. This technology has the potential to change that, giving transplant teams the time and information they need to make the most of organs that would otherwise go unused.”
Broader Implications for Lung Health
Jonathan Blades, head of policy at Asthma + Lung UK, highlighted the urgency of addressing the UK’s low lung transplant rates compared to other developed nations. He stated, “Renewed political and research focus is needed to transform lung health in the UK, and this new technology marks an important step towards that ambition.” The hope is that the XVIVO system will not only extend the viability of donated lungs but also improve outcomes for patients with severe lung conditions, allowing them more time with their loved ones.
Professor Andrew Fisher, a member of the British Transplantation Society, emphasised the need for rigorous evidence to validate the impact of the XVIVO device on transplant activity. He remarked, “It’s important that robust evidence is generated that shows exactly how much impact the use of this device has on lung transplant activity and supports timely access to transplant for patients desperately waiting for a suitable organ.”
Why it Matters
The introduction of the XVIVO perfusion system represents a pivotal moment for lung transplantation in the UK, with the potential to transform countless lives. As the country grapples with a critical shortage of viable organs, this innovative technology could unlock hundreds of previously discarded lungs, providing hope to patients who have long awaited a life-saving transplant. This development not only addresses the immediate need for more accessible lung transplants but also signifies a broader commitment to enhancing lung health across the nation.